Mumbai: Reliance-owned Karkinos Healthcare has crossed the milestone of conducting more than one lakh HPV DNA tests, marking a significant step in expanding access to cervical cancer screening across India. The achievement highlights the growing adoption of molecular diagnostics aimed at improving early detection and preventive healthcare.
Reliance-owned Karkinos Healthcare has completed over 100,000 HPV DNA tests, reinforcing its efforts to strengthen cervical cancer screening through advanced molecular diagnostics. The milestone reflects increasing awareness of preventive healthcare and the need for wider access to early detection services across the country.
Human Papillomavirus (HPV) infection is the leading cause of cervical cancer, making timely screening an important component of women’s healthcare. HPV DNA testing is designed to identify high-risk virus strains before the disease progresses, enabling earlier clinical intervention and improving treatment outcomes.
According to the company, the testing programme has expanded across multiple regions through its network of diagnostic laboratories, hospitals and healthcare partners. The initiative aims to improve access to quality screening while supporting national efforts to reduce the burden of cervical cancer.
Karkinos Healthcare said the milestone represents growing confidence among healthcare providers and patients in molecular testing as an effective screening tool. The company has continued to invest in diagnostic infrastructure, laboratory capabilities and technology-driven healthcare services to strengthen preventive care delivery.
The organisation noted that wider adoption of HPV DNA testing can help identify high-risk cases earlier than conventional screening methods in eligible populations, allowing clinicians to initiate timely follow-up and treatment when required.
The achievement also reflects the broader shift towards precision diagnostics in India’s healthcare ecosystem, where advanced laboratory technologies are playing a larger role in disease prevention and population health management.
As demand for preventive screening continues to rise, Karkinos Healthcare plans to further strengthen its diagnostic network and collaborate with healthcare institutions to improve access to evidence-based cancer screening services. The company said expanding early detection remains central to its long-term approach to reducing the impact of cervical cancer and supporting better health outcomes for women across India.
Source: This article is based on an official press release issued by Reliance Industries
MR_Reliance_owned_Karkinos_Healthcare_crosses_one_lakh_HPV_DNA_tests.pdf
